PTGS2 and breast carcinoma: In another randomized, placebo-controlled phase II clinical trial, the perioperative inhibition of β-ARs and cyclooxygenase-2 (COX-2) in breast cancer patients significantly suppressed the expression of genes related to epithelial-mesenchymal transition.